Alzheimer’s

Fuatilia
Scientist in lab examining a mouse with nanobody diagrams in background, illustrating promising research on camelid antibodies for brain disorders.
Àwòrán tí AI ṣe

Camelid nanobodies show promise for brain disorders in mice, review says

Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo

A Cell Press review published on November 5, 2025, highlights tiny camelid-derived antibodies known as nanobodies as potential tools for treating conditions such as Alzheimer’s disease and schizophrenia. The authors say these proteins can reach brain targets in mice more readily than conventional antibodies and outline key steps before human testing.

Ojú-ìwé yìí nlo kuki

A nlo kuki fun itupalẹ lati mu ilọsiwaju wa. Ka ìlànà àṣírí wa fun alaye siwaju sii.
Kọ